Community lists
चयनित · स्वास्थ्य सेवा

Biotech

InspectStocks द्वाराPublished 14 अक्टू॰ 202619 companies0 follower

Drug developers with approved medicines, built mainly on biologic and genetic science.

एक AI मॉडल की मदद से समूहबद्ध और हमारे संपादकों द्वारा जाँचा गया। हर कंपनी के नीचे की पंक्ति बताती है कि वह यहाँ क्यों है।

Sign in to followSign in to copy
Download image
कार्डस्तर

शेयर मूल्य 11 नव॰ 2026 के समापन मूल्य हैं, IEX एक्सचेंज फ़ीड से।

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+29.0%

  • VRTXVERTEX PHARMACEUTICALS INC / MA

    BiotechnologyMarket cap $138.7BP/E 35.22

    $547.02+26.0%1Y

    Since added +12.7%

    B+
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    स्थिर
    Business quality
    मज़बूत
    Getting better
    सुधर रही है

    Revenue

    $13B+10.5%

    Profit

    $4B+8.2%

    Free cash flow

    $3.2B-4.0%
    Discuss
    Why it is here: Develops and sells cystic fibrosis and other medicines
  • REGNREGENERON PHARMACEUTICALS, INC.

    BiotechnologyMarket cap $101.3BP/E 21.18

    $959.45+41.5%1Y

    Since added +27.4%

    C+
    वृद्धि और नकदी
    बढ़ रही है
    Business trend
    तेज़ हो रहा
    Business quality
    मज़बूत
    Getting better
    सुधर रही है

    Revenue

    $16.9B+18.6%

    Profit

    $4.8B+5.2%

    Free cash flow

    $3.8B-9.4%
    Discuss
    Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
  • GILDGILEAD SCIENCES, INC.

    Drug manufacturers generalMarket cap $210.5BP/E नहीं (परिचालन घाटा)

    $169.73+40.9%1Y

    Since added +14.8%

    A
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    स्थिर
    Business quality
    मिश्रित
    Getting better
    सुधर रही है

    Revenue

    $31B+6.5%

    Profit

    -$3.9B-147.6%

    Free cash flow

    $13.8B+50.4%
    Discuss
    Why it is here: Sells medicines for HIV, liver disease and cancer
  • ALNYALNYLAM PHARMACEUTICALS, INC.

    BiotechnologyMarket cap $21.4BP/E 68.58

    $159.80-64.7%1Y

    Since added -28.6%

    B+
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    धीमा हो रहा
    Business quality
    मज़बूत
    Getting better
    सुधर रही है

    Revenue

    $3.7B+65.2%

    Profit

    $2.6B+2,136.9%

    Free cash flow

    $465.4M+1,192.7%
    Discuss
    Why it is here: Develops and sells RNAi therapeutics
  • BIIBBIOGEN INC.

    Drug manufacturers generalMarket cap $37.5BP/E 109.22

    $253.39+56.9%1Y

    Since added +10.7%

    A
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    स्थिर
    Business quality
    ठोस
    Getting better
    मिश्रित

    Revenue

    $10.3B+2.3%

    Profit

    $347.5M-78.4%

    Free cash flow

    $2.1B-10.1%
    Discuss
    Why it is here: Develops and sells therapies for neurological diseases
  • INSMINSMED INC

    BiotechnologyMarket cap $26.5BP/E नहीं (परिचालन घाटा)

    $120.64-37.9%1Y

    Since added +24.7%

    C-
    वृद्धि और नकदी
    बढ़ रही है
    Business trend
    स्थिर
    Business quality
    कमज़ोर
    Getting better
    मिश्रित

    Revenue

    $1.5B+240.0%

    Profit

    -$605.6M+48.8%

    Free cash flow

    -$627.6M+30.7%
    Discuss
    Why it is here: Develops and sells therapies for rare lung diseases
  • UTHRUnited Therapeutics Corporation

    Drug manufacturers specialty and genericMarket cap $25.4BP/E 22.48

    $595.58+29.0%1Y

    Since added +9.6%

    C+
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    धीमा हो रहा
    Business quality
    मज़बूत
    Getting better
    तेज़ी से सुधर रही है

    Revenue

    $3.2B+1.9%

    Profit

    $1.2B-3.2%

    Free cash flow

    $867.2M-22.7%
    Discuss
    Why it is here: Sells therapies for pulmonary arterial hypertension
  • NBIXNEUROCRINE BIOSCIENCES, INC.

    Drug manufacturers specialty and genericMarket cap $17.6BP/E 25.87

    $174.35+18.7%1Y

    Since added +29.0%

    A+
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    तेज़ हो रहा
    Business quality
    मज़बूत
    Getting better
    सुधर रही है

    Revenue

    $3.7B+38.0%

    Profit

    $702.5M+64.1%

    Free cash flow

    $1B+75.3%
    Discuss
    Why it is here: Develops and sells therapies for neurological and endocrine disorders
  • MRNAModerna, Inc.

    BiotechnologyMarket cap $100.6BP/E नहीं (परिचालन घाटा)

    $248.70+831.1%1Y

    Since added +15.0%

    C-
    वृद्धि और नकदी
    बढ़ रही है
    Business trend
    तेज़ हो रहा
    Business quality
    कमज़ोर
    Getting better
    बिगड़ रही है

    Revenue

    $2.5B+13.1%

    Profit

    -$2.8B+10.5%

    Free cash flow

    -$2B+25.7%
    Discuss
    Why it is here: Develops mRNA vaccines and therapies
  • BMRNBioMarin Pharmaceutical Inc

    BiotechnologyMarket cap $11.3BNo P/E

    $58.32+5.4%1Y

    Since added +7.3%

    B
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    स्थिर
    Business quality
    मिश्रित
    Getting better
    सुधर रही है

    Revenue

    $3.7B+18.1%

    Profit

    -$19.1M-103.7%

    Free cash flow

    $557.9M-33.0%
    Discuss
    Why it is here: Develops and sells therapies for rare genetic diseases
  • INCYINCYTE CORPORATION

    BiotechnologyMarket cap $24.9BP/E 65.01

    $122.23+12.9%1Y

    Since added +12.6%

    C
    लाभ और बही मूल्य
    बढ़ रही है
    Business quality
    मिश्रित
    Getting better
    तेज़ी से सुधर रही है

    Revenue

    $6B+24.9%

    Profit

    $403.4M-66.1%

    Free cash flow

    $892.1MNo comparable year
    Discuss
    Why it is here: Develops and sells oncology and inflammation therapies
  • EXELEXELIXIS, INC.

    BiotechnologyMarket cap $17.3BP/E 21.17

    $70.71+62.2%1Y

    Since added +18.8%

    A+
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    स्थिर
    Business quality
    मज़बूत
    Getting better
    सुधर रही है

    Revenue

    $2.5B+9.1%

    Profit

    $885.1M+30.6%

    Free cash flow

    $1.2B+48.9%
    Discuss
    Why it is here: Develops and sells cancer therapies
  • BNTXBioNTech SE

    BiotechnologyMarket cap $22BP/E नहीं (परिचालन घाटा)

    $87.64-21.5%1Y

    Since added -1.5%

    F
    वृद्धि और नकदी
    मिश्रित
    Business trend
    सिकुड़ रहा
    Business quality
    मिश्रित
    Getting better
    सुधर रही है

    Revenue

    $2.7B-23.2%

    Profit

    -$1.6B-157.7%

    Free cash flow

    $314M+456.5%
    Discuss
    Why it is here: Develops mRNA vaccines and cancer therapies
  • JAZZJazz Pharmaceuticals plc

    BiotechnologyMarket cap $15.9BP/E 80.84

    $248.18+81.5%1Y

    Since added +18.0%

    A
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    स्थिर
    Business quality
    मिश्रित
    Getting better
    सुधर रही है

    Revenue

    $4.7B+13.5%

    Profit

    $206M+155.9%

    Free cash flow

    $1.6B+21.3%
    Discuss
    Why it is here: Develops and sells neuroscience and oncology therapies
  • HALOHALOZYME THERAPEUTICS, INC.

    BiotechnologyMarket cap $11.6BP/E 25.36

    $101.69+44.0%1Y

    Since added -7.2%

    A+
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    स्थिर
    Business quality
    मज़बूत
    Getting better
    सुधर रही है

    Revenue

    $1.8B+45.0%

    Profit

    $485.4M-18.5%

    Free cash flow

    $885.9M+47.1%
    Discuss
    Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
  • ASNDAscendis Pharma A/S

    BiotechnologyMarket cap $16.1BP/E नहीं (परिचालन घाटा)

    $259.10+30.1%1Y

    Since added +16.0%

    D
    लाभ और बही मूल्य
    मिश्रित
    Business quality
    मिश्रित
    Getting better
    सुधर रही है

    Revenue

    $1.2B+113.4%

    Profit

    -$254.8M+39.7%

    Free cash flow

    -$293.2M+54.2%
    Discuss
    Why it is here: Develops and sells endocrinology rare disease therapies
  • BBIOBridgeBio Pharma, Inc.

    BiotechnologyMarket cap $15.5BP/E नहीं (परिचालन घाटा)

    $79.53+20.1%1Y

    Since added +25.6%

    B
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    स्थिर
    Business quality
    मिश्रित
    Getting better
    बिगड़ रही है

    Revenue

    $945.5M+167.3%

    Profit

    -$573.8M+28.6%

    Free cash flow

    -$369.8M+36.9%
    Discuss
    Why it is here: Develops therapies for genetic diseases
  • CORTCORCEPT THERAPEUTICS INC

    BiotechnologyMarket cap $8.2BP/E 58.68

    $74.52-4.9%1Y

    Since added -36.7%

    A+
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    तेज़ हो रहा
    Business quality
    मज़बूत
    Getting better
    मिश्रित

    Revenue

    $963.6M+30.0%

    Profit

    $162.3M+52.9%

    Free cash flow

    $194.6M+19.2%
    Discuss
    Why it is here: Develops and sells cortisol-modulating therapies
  • KRYSKrystal Biotech, Inc.

    BiotechnologyMarket cap $9.2BP/E 41.90

    $308.82+52.1%1Y

    Since added -3.9%

    A+
    वृद्धि और नकदी
    मज़बूती से बढ़ रही है
    Business trend
    स्थिर
    Business quality
    मज़बूत
    Getting better
    सुधर रही है

    Revenue

    $470M+26.0%

    Profit

    $225.2M+13.2%

    Free cash flow

    $310.1M+87.3%
    Discuss
    Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Sign in to join the discussion

Be civil and stick to the companies. Comments are opinions, not advice.

    Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.